SIC
TVTX icon

SJS Investment Consulting’s Travere Therapeutics TVTX Stock Holding History

SJS Investment Consulting’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5K Buy
44
+30
+214% +$1.33K ﹤0.01% 1680
2026
Q1 		$416 Sell
14
-1
-7% -$30 ﹤0.01% 1802
2025
Q4 		$574 Buy
+15
New +$488 ﹤0.01% 1479

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

SJS Investment Consulting's TVTX Position: Q2 2026 in Review

SJS Investment Consulting increased its Travere Therapeutics (TVTX) stake by 214% in Q2 2026, buying an estimated $1.33K and bringing the position to 44 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1680.

SJS Investment Consulting first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • SJS Investment Consulting held 44 shares of Travere Therapeutics worth $2.5K as of Q2 2026.
  • SJS Investment Consulting bought 30 Travere Therapeutics shares in Q2 2026, an estimated $1.33K.
  • Travere Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1680 holding.
  • SJS Investment Consulting first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.